<DOC>
	<DOCNO>NCT00950534</DOCNO>
	<brief_summary>The primary objective demonstrate improvement glycosylated haemoglobin ( HbA1c ) level general practitioner ( GP ) initiation management type 2 diabetes mellitus ( T2DM ) insulin glargine compare usual clinical practice . The secondary objective demonstrate importance GP initiation insulin glargine treatment T2DM .</brief_summary>
	<brief_title>Effectiveness Safety Two Approaches Management Type 2 Diabetes Mellitus Australian Primary Care</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Inclusion criterion : Diagnosed type 2 Diabetes Mellitus ( T2DM ) HbA1c &gt; = 7.5 % , HbA1c &lt; = 10 % Continuous oral antidiabetic ( OAD ) treatment equal three month randomisation stable daily dose one OADs ( two OADs , one must less equal half maximum tolerate dose ) Willing able perform blood glucose monitoring use blood glucose meter Willing able keep daily patient diary Willing able provide write informed consent enrolment study Exclusion criterion : Type 1 diabetes mellitus Body mass index ( BMI ) &gt; 45 kg/m² Works night shift History ketoacidosis hyperosmolar hyperglycaemic state History stroke , myocardial infarction , angina pectoris , coronary artery bypass graft percutaneous transluminal coronary angioplasty within previous 12 month History congestive heart failure Hypoglycaemia unawareness Have one episode hypoglycaemia ( per protocol definition ) within 24 week screen Impaired renal function define , limited , serum creatinine &gt; = 1.5 mg/dL ( 133 µmol/L ) males &gt; = 1.4 mg/dL ( 124 µmol/L ) females Active liver disease ( alanine transaminase ( ALT ) great two time upper limit reference range , define local laboratory ) Have condition ( include know substance alcohol abuse psychiatric disorder ) preclude patient follow complete study protocol Had blood transfusion severe blood loss within 3 month screen , know haemoglobinopathy , haemolytic anaemia sickle cell anaemia Current previous use insulin Known hypersensitivity / intolerance insulin glargine excipients Have take exenatide six week screen total 30 day 24 week screen Currently receive treatment nonselective blocker Currently receive chronic ( longer two week ) systemic glucocorticoid therapy ( exclude topical inhale preparation ) receive therapy within four week precede screen visit Currently undergo therapy plan radiological examination require administration contrast agent malignancy ( nonmetastatic / early stage basal cell squamous cell carcinoma ) . Currently participate another investigational study recent study participation end &lt; 30 day screen Female patient pregnant breastfeed Female patient childbearing potential ( i.e. , ovulate , premenopausal , surgically sterile ) must willing agree use medically accept contraceptive regimen duration study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>